Abstract
Classic Ph negative chronic myeloproliferative neoplasms (MPN) comprise polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), which are characterized by stem cell-derived clonal myeloproliferative diseases. Thrombotic complications are main reasons of morbidity and mortality in patients with MPN. At present, studies indicate that the most important risk factors of thrombosis in MPN patients are advanced age (>60 years old) and previous history of thrombosis. High white blood cell count and leukocyte activation are risk factors for thrombosis. Studies have pointed out Janus kinase (JAK) 2V617F, calreticulin (CALR), MPL and other genes mutation also affect the thrombosis of MPN. MPN patients need to be assessed the risk of thrombosis before treatment, and received a purposeful and different treatment. This article focuses on thrombosis risks against MPN patients with advanced age (>60 years old), history of thrombosis, cardiovascular events risk factors, JAK2, MPL, CALR gene mutations or leucocytosis and the treatment of MPN. Key words: Thrombosis; Thrombocytosis; Polycythemia; Myeloproliferative neoplasma; Mutation; Leukocyte count
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
